altretamine has been researched along with carboplatin in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (25.00) | 18.7374 |
| 1990's | 11 (68.75) | 18.2507 |
| 2000's | 1 (6.25) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ozols, RF | 1 |
| Dalesio, O; Dubbelman, R; Franklin, H; Hilton, A; Koier, I; Rodenhuis, S; ten Bokkel Huinink, WW; van der Burg, ME; van Oosterom, AT; van Tinteren, H | 1 |
| Muggia, F; Norris, K | 1 |
| Frankendal, B; Himmelmann, A; Scheistrøen, M; Tropé, C; Vergote, I; Vlachos, K | 1 |
| Korn, EL; Simon, R | 1 |
| Belloni, C; Bianchi, U; Bolis, G; Bonazzi, C; Colombo, N; Epis, A; Favalli, G; Marsoni, S; Torri, V; Valsecchi, MG | 1 |
| Ozols, RF; Poirier, MC; Reed, E; Tarone, R; Yuspa, SH | 1 |
| Dalesio, O; George, M; Guastalla, JP; Neijt, JP; Rotmensz, N; ten Bokkel Huinink, WW; van der Burg, ME; van Oosterom, AT; Veenhof, CH; Vermorken, JB | 1 |
| Roosendaal, K; ten Bokkel Huinink, WW; vd Burg, ME; Veenhof, C; Vermorken, JB; von Oosterom, AT | 1 |
| Balducci, L; Khansur, T; Thigpen, JT; Vance, RB | 1 |
| Heinonen, E; Hinkka, SM; Karnani, P; Klemi, PJ; Korpijaakko, TA; Kuoppala, TA; Lähde, MA; Laine, AM; Mäenpää, JU; Nuoranne, EK | 1 |
| Comella, G; Comella, P; Conforti, S; Frasci, G; Mastrantonio, P; Persico, G; Zullo, F | 1 |
| Hryniuk, W; Levin, L; Simon, R | 1 |
| Baekelandt, M; Kristensen, GB; Tropé, C; Vergote, IB | 1 |
| Chang, C; Imamura, K; Nishimura, H | 1 |
| Herzog, TJ | 1 |
4 review(s) available for altretamine and carboplatin
| Article | Year |
|---|---|
Role of chemotherapy in the future treatment of ovarian cancer.
Topics: Alkaloids; Altretamine; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Female; Humans; Ovarian Neoplasms; Paclitaxel; Remission Induction | 1992 |
New drugs and experimental approaches in ovarian cancer treatment.
Topics: Altretamine; Aminoacridines; Amsacrine; Antineoplastic Agents; Aziridines; Benzoquinones; Busulfan; Carboplatin; Cisplatin; Estrogen Antagonists; Female; Galactitol; Humans; Ifosfamide; Mitomycins; Organoplatinum Compounds; Ovarian Neoplasms; Prednimustine; Progestins | 1984 |
[Chemotherapy for recurrent ovarian cancer].
Topics: Adenocarcinoma, Clear Cell; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel | 1996 |
Recurrent ovarian cancer: how important is it to treat to disease progression?
Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Recurrence; Risk; Taxoids; Time Factors; Topotecan | 2004 |
6 trial(s) available for altretamine and carboplatin
| Article | Year |
|---|---|
Replacement of cisplatin with carboplatin in combination chemotherapy against ovarian cancer: long-term treatment results of a study of the Gynaecological Cancer Cooperative Group of the EORTC and experience at The Netherlands Cancer Institute.
Topics: Adult; Aged; Aged, 80 and over; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Doxorubicin; Europe; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Netherlands; Ovarian Neoplasms; Remission Induction; Survival Rate | 1992 |
Carboplatin in combination therapy for ovarian cancer.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Female; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Prospective Studies; Random Allocation | 1988 |
A pilot study of CHAC-1.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Humans; Middle Aged; Neoplasms; Organoplatinum Compounds | 1985 |
The subrenal capsule assay in selecting chemotherapy for ovarian cancer: a prospective randomized trial.
Topics: Aged; Altretamine; Animals; Antineoplastic Combined Chemotherapy Protocols; Carbazilquinone; Carboplatin; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Methotrexate; Mice; Mice, Inbred Strains; Middle Aged; Ovarian Neoplasms; Prospective Studies; Subrenal Capsule Assay; Tegafur | 1995 |
Carboplatin (CBDCA)-hexamethylmelamine (HMM)-oral etoposide (VP-16) first-line treatment of ovarian cancer patients with bulky disease: a phase II study.
Topics: Administration, Oral; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Etoposide; Female; Follow-Up Studies; Humans; Middle Aged; Ovarian Neoplasms | 1995 |
A phase II study of carboplatin and hexamethylmelamine as induction chemotherapy in advanced epithelial ovarian carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Female; Humans; Middle Aged; Ovarian Neoplasms; Survival Rate | 1995 |
6 other study(ies) available for altretamine and carboplatin
| Article | Year |
|---|---|
Hexamethylmelamine in platinum-resistant ovarian cancer: how active?
Topics: Altretamine; Carboplatin; Cisplatin; Drug Resistance; Female; Humans; Ovarian Neoplasms | 1992 |
Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Altretamine; Carboplatin; Cisplatin; Drug Resistance; Female; Humans; Middle Aged; Ovarian Neoplasms | 1992 |
Selecting drug combinations based on total equivalent dose (dose intensity)
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Models, Theoretical; Organoplatinum Compounds; Ovarian Neoplasms | 1990 |
Prognostic factors in advanced epithelial ovarian cancer. (Gruppo Interregionale Cooperativo di Oncologia Ginecologica (GICOG)).
Topics: Age Factors; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Doxorubicin; Female; Humans; Ovarian Neoplasms; Prognosis; Regression Analysis; Survival Analysis | 1990 |
Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy.
Topics: Adult; Aged; Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Cyclophosphamide; DNA Damage; DNA, Neoplasm; Drug Evaluation; Female; Humans; Middle Aged; Misonidazole; Organoplatinum Compounds; Ovarian Neoplasms | 1987 |
Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Ovarian Neoplasms; Regression Analysis | 1993 |